CN105131113B - 用于宫颈癌检测和分级的单隆抗体及其应用 - Google Patents
用于宫颈癌检测和分级的单隆抗体及其应用 Download PDFInfo
- Publication number
- CN105131113B CN105131113B CN201510530457.8A CN201510530457A CN105131113B CN 105131113 B CN105131113 B CN 105131113B CN 201510530457 A CN201510530457 A CN 201510530457A CN 105131113 B CN105131113 B CN 105131113B
- Authority
- CN
- China
- Prior art keywords
- antibody
- protein
- cancer
- cervical
- hpv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims description 53
- 208000019065 cervical carcinoma Diseases 0.000 title abstract description 4
- 210000001519 tissue Anatomy 0.000 claims abstract description 53
- 230000003902 lesion Effects 0.000 claims abstract description 46
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 43
- 241000341655 Human papillomavirus type 16 Species 0.000 claims abstract description 18
- 238000003745 diagnosis Methods 0.000 claims abstract description 17
- 201000011510 cancer Diseases 0.000 claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 83
- 102000004169 proteins and genes Human genes 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 69
- 210000004027 cell Anatomy 0.000 claims description 68
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 60
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 60
- 201000010881 cervical cancer Diseases 0.000 claims description 60
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 50
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 50
- 229920001184 polypeptide Polymers 0.000 claims description 49
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims description 47
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 29
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 29
- 230000027455 binding Effects 0.000 claims description 27
- 238000009739 binding Methods 0.000 claims description 26
- 230000014509 gene expression Effects 0.000 claims description 25
- 238000002965 ELISA Methods 0.000 claims description 20
- 101000767629 Human papillomavirus type 18 Protein E7 Proteins 0.000 claims description 20
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 16
- 108091033319 polynucleotide Proteins 0.000 claims description 16
- 102000040430 polynucleotide Human genes 0.000 claims description 16
- 239000002157 polynucleotide Substances 0.000 claims description 16
- 238000003556 assay Methods 0.000 claims description 15
- 239000012188 paraffin wax Substances 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 229940127121 immunoconjugate Drugs 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 206010014733 Endometrial cancer Diseases 0.000 claims description 7
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 7
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 7
- 206010034299 Penile cancer Diseases 0.000 claims description 7
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 238000011161 development Methods 0.000 claims description 6
- 230000002055 immunohistochemical effect Effects 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 231100000765 toxin Toxicity 0.000 claims description 5
- 210000002229 urogenital system Anatomy 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 238000003364 immunohistochemistry Methods 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 108010067390 Viral Proteins Proteins 0.000 claims description 3
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 3
- 230000006037 cell lysis Effects 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000011061 large intestine cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 201000002314 small intestine cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 210000002249 digestive system Anatomy 0.000 claims description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 2
- 238000002271 resection Methods 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 238000012286 ELISA Assay Methods 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 239000013592 cell lysate Substances 0.000 claims 1
- 238000009826 distribution Methods 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract description 62
- 208000009608 Papillomavirus Infections Diseases 0.000 abstract description 10
- 239000000090 biomarker Substances 0.000 abstract description 4
- 208000037581 Persistent Infection Diseases 0.000 abstract description 3
- 210000003679 cervix uteri Anatomy 0.000 abstract description 3
- 210000000981 epithelium Anatomy 0.000 abstract description 2
- 231100000915 pathological change Toxicity 0.000 abstract description 2
- 230000036285 pathological change Effects 0.000 abstract description 2
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004745 cervical carcinogenesis Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 241000701806 Human papillomavirus Species 0.000 description 46
- 206010008263 Cervical dysplasia Diseases 0.000 description 43
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 40
- 238000010186 staining Methods 0.000 description 32
- 125000003275 alpha amino acid group Chemical group 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 238000005406 washing Methods 0.000 description 27
- 108091007433 antigens Proteins 0.000 description 25
- 102000036639 antigens Human genes 0.000 description 25
- 239000000427 antigen Substances 0.000 description 24
- 239000012634 fragment Substances 0.000 description 22
- 238000001035 drying Methods 0.000 description 21
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 15
- 102000037865 fusion proteins Human genes 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 238000011160 research Methods 0.000 description 10
- 238000011532 immunohistochemical staining Methods 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 108091008819 oncoproteins Proteins 0.000 description 8
- 102000027450 oncoproteins Human genes 0.000 description 8
- 238000007789 sealing Methods 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 239000006180 TBST buffer Substances 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000002823 phage display Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000002791 soaking Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 208000009458 Carcinoma in Situ Diseases 0.000 description 4
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 description 4
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 101710130607 Valacyclovir hydrolase Proteins 0.000 description 4
- 102100025139 Valacyclovir hydrolase Human genes 0.000 description 4
- 201000003565 cervix uteri carcinoma in situ Diseases 0.000 description 4
- 238000002591 computed tomography Methods 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 238000012760 immunocytochemical staining Methods 0.000 description 4
- 201000004933 in situ carcinoma Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 208000022159 squamous carcinoma in situ Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 208000022625 uterine cervix carcinoma in situ Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000276498 Pollachius virens Species 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000000984 immunochemical effect Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000439 tumor marker Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 244000050510 Cunninghamia lanceolata Species 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000729176 Fagopyrum dibotrys Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000009841 epithelial lesion Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002073 nanorod Substances 0.000 description 2
- 230000009125 negative feedback regulation Effects 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- AUXMWYRZQPIXCC-KNIFDHDWSA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O AUXMWYRZQPIXCC-KNIFDHDWSA-N 0.000 description 1
- WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
- PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
- LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 206010061809 Cervix carcinoma stage 0 Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- WEMYTDDMDBLPMI-DKIMLUQUSA-N Phe-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N WEMYTDDMDBLPMI-DKIMLUQUSA-N 0.000 description 1
- YTILBRIUASDGBL-BZSNNMDCSA-N Phe-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 YTILBRIUASDGBL-BZSNNMDCSA-N 0.000 description 1
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- ARJASMXQBRNAGI-YESZJQIVSA-N Tyr-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N ARJASMXQBRNAGI-YESZJQIVSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000003450 affinity purification method Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003131 biological toxin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000002573 colposcopy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 201000010255 female reproductive organ cancer Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000024312 invasive carcinoma Diseases 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
最初的残基 | 代表性的取代 | 优选的取代 |
Ala(A) | Val;Leu;Ile | Val |
Arg(R) | Lys;Gln;Asn | Lys |
Asn(N) | Gln;His;Lys;Arg | Gln |
Asp(D) | Glu | Glu |
Cys(C) | Ser | Ser |
Gln(Q) | Asn | Asn |
Glu(E) | Asp | Asp |
Gly(G) | Pro;Ala | Ala |
His(H) | Asn;Gln;Lys;Arg | Arg |
Ile(I) | Leu;Val;Met;Ala;Phe | Leu |
Leu(L) | Ile;Val;Met;Ala;Phe | Ile |
Lys(K) | Arg;Gln;Asn | Arg |
Met(M) | Leu;Phe;Ile | Leu |
Phe(F) | Leu;Val;Ile;Ala;Tyr | Leu |
Pro(P) | Ala | Ala |
Ser(S) | Thr | Thr |
Thr(T) | Ser | Ser |
Trp(W) | Tyr;Phe | Tyr |
Tyr(Y) | Trp;Phe;Thr;Ser | Phe |
Val(V) | Ile;Leu;Met;Phe;Ala | Leu |
Claims (32)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510530457.8A CN105131113B (zh) | 2015-08-26 | 2015-08-26 | 用于宫颈癌检测和分级的单隆抗体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510530457.8A CN105131113B (zh) | 2015-08-26 | 2015-08-26 | 用于宫颈癌检测和分级的单隆抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105131113A CN105131113A (zh) | 2015-12-09 |
CN105131113B true CN105131113B (zh) | 2019-09-06 |
Family
ID=54716730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510530457.8A Active CN105131113B (zh) | 2015-08-26 | 2015-08-26 | 用于宫颈癌检测和分级的单隆抗体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105131113B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107556379B (zh) * | 2016-07-01 | 2021-05-28 | 艾托金生物医药(苏州)有限公司 | 识别高危hpv e7蛋白的单克隆抗体及其应用 |
CN107868127A (zh) * | 2016-09-28 | 2018-04-03 | 艾托金生物医药(苏州)有限公司 | 一种用于检测病理组织切片中癌蛋白表达的单克隆抗体 |
JP7401312B2 (ja) | 2017-06-28 | 2023-12-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ヒトパピローマウイルス(hpv)抗原結合性タンパク質およびその使用方法 |
CN109425527B (zh) * | 2017-09-04 | 2021-10-01 | 艾托金生物医药(苏州)有限公司 | 一种细胞染色方法 |
CN108285479B (zh) * | 2018-02-02 | 2020-07-03 | 南华大学 | 七肽及其在制备治疗和/或诊断宫颈癌的产品中的应用 |
CN114874326B (zh) * | 2022-06-21 | 2023-01-17 | 图凌(杭州)生物医药有限公司 | 一种检测雌激素受体α的单克隆抗体及其制备方法和应用 |
CN116063485A (zh) * | 2022-11-29 | 2023-05-05 | 襄阳市中心医院 | p16蛋白单克隆抗体的制备方法、免疫试纸条、试剂盒及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101765607A (zh) * | 2007-05-31 | 2010-06-30 | 莱顿教学医院 | 侵润宫颈恶性肿瘤的t细胞所靶向的用于疫苗的hpv表位 |
EP2357197A1 (en) * | 2010-02-16 | 2011-08-17 | Österreichische Akademie der Wissenschaften | Anti-HPV E7 antibodies |
CN102399820A (zh) * | 2011-09-27 | 2012-04-04 | 天津佰思普生物科技有限公司 | 针对hpv16 e7基因的小干扰rna及其应用 |
CN102449479A (zh) * | 2009-05-07 | 2012-05-09 | 安科健康公司 | 鉴别高度或≥cin2用于人乳头瘤病毒(hpv)与hpv相关癌症的早期及晚期检测、筛检和诊断 |
CN102822672A (zh) * | 2010-01-08 | 2012-12-12 | 安科健康公司 | 用于诊断和筛选与hpv有关的癌症的高通量细胞基hpv免疫测定 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2712892T3 (es) * | 2010-02-16 | 2019-05-16 | Oesterreichische Akademie Der Wss | Anticuerpos anti-E7 del HPV |
-
2015
- 2015-08-26 CN CN201510530457.8A patent/CN105131113B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101765607A (zh) * | 2007-05-31 | 2010-06-30 | 莱顿教学医院 | 侵润宫颈恶性肿瘤的t细胞所靶向的用于疫苗的hpv表位 |
CN102449479A (zh) * | 2009-05-07 | 2012-05-09 | 安科健康公司 | 鉴别高度或≥cin2用于人乳头瘤病毒(hpv)与hpv相关癌症的早期及晚期检测、筛检和诊断 |
CN102822672A (zh) * | 2010-01-08 | 2012-12-12 | 安科健康公司 | 用于诊断和筛选与hpv有关的癌症的高通量细胞基hpv免疫测定 |
EP2357197A1 (en) * | 2010-02-16 | 2011-08-17 | Österreichische Akademie der Wissenschaften | Anti-HPV E7 antibodies |
CN102399820A (zh) * | 2011-09-27 | 2012-04-04 | 天津佰思普生物科技有限公司 | 针对hpv16 e7基因的小干扰rna及其应用 |
Non-Patent Citations (2)
Title |
---|
Antibodies against linear and conformational epitopes of the human papillomavirus(HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients;I.Nidl et al.;《Arch Virol》;19940930;第137卷(第3-4期);341-353 |
Prevalence of Serum Antibodies to Synthetic Peptides to HPV16 Epitopes Among Indian Women with Cervical Neoplasia;B.K.Sharma et al.;《European Journal of Cancer》;19960531;第34A卷(第5期);872-876 |
Also Published As
Publication number | Publication date |
---|---|
CN105131113A (zh) | 2015-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105131113B (zh) | 用于宫颈癌检测和分级的单隆抗体及其应用 | |
US10094832B2 (en) | Cervical cancer-related HPV E7 protein monoclonal antibody and use thereof | |
CN105524166B (zh) | 识别hpv18阳性宫颈上皮癌细胞的单克隆抗体及其应用 | |
EP2558501B1 (en) | Monoclonal antibodies against her2 antigens, and uses therefor | |
JP2010520768A (ja) | He4モノクローナル抗体およびそれらの使用方法 | |
JP2008539271A (ja) | csPCNAイソ型抗体およびその使用 | |
CN106366186B (zh) | 识别hpv16阳性肿瘤细胞的单克隆抗体及其应用 | |
WO2018059117A1 (zh) | 一种用于检测病理组织切片中癌蛋白表达的单克隆抗体 | |
CN107556379B (zh) | 识别高危hpv e7蛋白的单克隆抗体及其应用 | |
CN109575130B (zh) | 一种检测hpv18 e7蛋白的单克隆抗体及其制备和应用 | |
JP2009520024A (ja) | Mcm6モノクローナル抗体およびmcm7モノクローナル抗体ならびに子宮頚部疾患の検出におけるそれらの使用のための方法 | |
CN115073591B (zh) | 一种可识别asfv外膜糖基化修饰蛋白的单克隆抗体及应用 | |
KR20120095301A (ko) | 항-사이토케라틴 8/18 복합체 자가면역항체를 포함하는 암 진단 마커 및 이의 항원을 포함하는 암 진단용 조성물 | |
CN109593131B (zh) | 一种抗14-3-3η蛋白单克隆抗体及其用途 | |
CN109021097A (zh) | 一种识别hpv18和/或hpv45的单克隆抗体及其应用 | |
CN110540591A (zh) | 一种抗糖蛋白A33(Glycoprotein A33)单克隆抗体及其免疫检测应用 | |
CN109897109B (zh) | 抗肿瘤标志蛋白单克隆抗体及其用途 | |
CN116410306A (zh) | 一种检测宫颈癌蛋白hpv e6的单克隆抗体及应用 | |
CN116410305A (zh) | 一种用于检测宫颈癌病理组织中hpv16 e6蛋白的单克隆抗体 | |
CN116410321A (zh) | 一种检测宫颈癌细胞中内源蛋白hpv16 e6的单克隆抗体及其制备和应用 | |
JP6793514B2 (ja) | 新規甲状腺癌関連抗原に結合する抗体および甲状腺癌診断剤 | |
WO2023136779A2 (en) | Antibody sequences of three antibody candidates targeting human lymphocyte antigen 6 family member k (ly6k) | |
CN114213542A (zh) | Cps-i抗体及其用途 | |
CN114478779A (zh) | 人源化的磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Monoclonal antibody for detection and grading of cervical cancer and its application Effective date of registration: 20211020 Granted publication date: 20190906 Pledgee: Jiangsu Suzhou Rural Commercial Bank Co.,Ltd. science and Technology Financial Industrial Park sub branch Pledgor: ATTOGEN BIOMEDICAL (SUZHOU) Inc.,Ltd. Registration number: Y2021320010426 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20190906 Pledgee: Jiangsu Suzhou Rural Commercial Bank Co.,Ltd. science and Technology Financial Industrial Park sub branch Pledgor: ATTOGEN BIOMEDICAL (SUZHOU) Inc.,Ltd. Registration number: Y2021320010426 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Monoclonal antibodies for cervical cancer detection and grading and their applications Granted publication date: 20190906 Pledgee: Suzhou Beiming Intelligent Manufacturing Co.,Ltd. Pledgor: ATTOGEN BIOMEDICAL (SUZHOU) Inc.,Ltd. Registration number: Y2024990000122 |